Latest Insights - page 80 | BiopharmaTrend

Oxford Drug Design and PhoreMost collaborate to advance novel cancer therapeutics discovery

Oxford Drug Design, a biotechnology company with core expertise in computer-aided drug design, has announced that it has been engaged by PhoreMost Ltd (PhoreMost), a UK-based biopharmaceutical company dedicated to …

Continue ›››

The Potential of Artificial Intelligence to Transform the European Life Sciences Landscape (with a Caveat)

The adoption of artificial intelligence (AI) in life sciences has been rapidly expanding across the globe, and the European Union (EU) is no exception. With the increasing need for innovative …

Continue ›››

Altasciences Boosts Life-Saving Drug Development with Proscia's Digital Pathology Platform

In a strategic move to improve the drug development process, Altasciences has partnered with Proscia, a leading provider of digital and computational pathology solutions. The collaboration leverages Proscia's Concentriq® for …

Continue ›››

Proscia Enhances Preclinical R&D Platform: Streamlining Pathology Workflows for Faster Drug Safety Decisions

Proscia, a company specializing in digital and computational pathology solutions, recently announced updates to its preclinical research and development (R&D) offerings. These improvements target the company's flagship software platform, Concentriq® …

Continue ›››

Breaking Through the Investment Gap: Mark Andrews Discusses British Patient Capital's Life Sciences Fund

In this interview, we speak with Mark Andrews, Investment Director, Life Sciences, Funds at British Patient Capital, the largest domestic investor into UK venture capital opportunities, including pharmaceutical industry and …

Continue ›››

Biopharma Financial Climate and Market Dynamics in 2023: Interview with David Dowling, Ropes & Gray

Recently, David Dowling, a senior lawyer at Ropes & Gray, has outlined his predictions for M&A in the European biotech sector in 2023 in his blog Why 2023 is set to …

Continue ›››

The Time for Breakthroughs in Antibiotic Discovery

Since a revolutionary discovery of penicillin in 1928 by Scottish bacteriologist and Nobel laureate Alexander Fleming, numerous inventions of new antibiotic classes followed. A cascade of discoveries over decades pushed …

Continue ›››

British Patient Capital Backs Notable Cancer Research with $7 million Investment in Grey Wolf Therapeutics

British Patient Capital, a subsidiary of the British Business Bank, invested $7 million in Grey Wolf Therapeutics, an Oxford-based biotech company that is developing first-of-its-kind cancer therapies. The investment was …

Continue ›››

Democratizing Early Drug Discovery through Artificial Intelligence: Interview with Syntekabio CEO Jongsun Jung

15 Biopharma Research Trends to Watch in 2022

Table of contents: mRNA vaccines and RNA therapies Epitranscriptomics Targeting RNA with small molecules Deep learning and big data in drug discovery Neoantigens Theranostics Exosomes Synthetic Biology 3D Bioprinting …

Continue ›››

A Look at Longevity Industry: Interview with Dr. Eric Leire, CEO of Genflow Biosciences

The aging research industry has exploded in recent years. Once a fringe area of science, aging research has now gained widespread recognition for its potential to address the challenges of …

Continue ›››

Innovation and Sustainability Trends for 2023: Interview with Jesper Jonsson, Director of Medical Devices at Owen Mumford

The medical device industry is driven by constant innovation, and the annual Medica conference offers the chance to discover the latest advancements propelling the sector forward. Jesper Jonsson, Director of …

Continue ›››